Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1a, Randomized, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RN5681 in Healthy Volunteers

Next Previous
Trial Profile

A Phase 1a, Randomized, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RN5681 in Healthy Volunteers

Status: Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 21 Jan 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs RN 5681 (Primary)
  • Indications Atherosclerosis
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors Ikaria Bioscience

Most Recent Events

  • 16 Jan 2026 Status changed from planning to not yet recruiting.
  • 31 Dec 2025 New trial record
  • 17 Dec 2025 According to Rona Therapeutics media release, the company announced the submission of RN5681 to the Australian Human Research Ethics Committee (HREC), this trial expected to begin dosing in Q1 2026.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top